Angiotensin Converting Enzymes Inhibitors Market Synopsis

Angiotensin Converting Enzymes Inhibitors Market Size Was Valued at USD 8072.6 Million in 2023 and is Projected to Reach USD 13408.63 Million by 2032, Growing at a CAGR of 5.8 % From 2024-2032.

The Angiotensin-converting enzyme (ACE) Inhibitors Market is the global industry that deals in research, manufacturing, and sales of ACE inhibitors which are a group of drugs used to treat hypertension and related cardiac diseases. ACE inhibitors act to limit the production of the substance that constricts the blood vessels since the lack of this substance leads to a lowering of blood pressure. Through their actions of inhibiting the formation of angiotensin II, these drugs result in the dilation of blood vessels, decrease in blood pressure, and also enhance blood flow, factors which reduce risks of such conditions as heart attack, stroke, and kidney failure. ACE inhibitors in this market include lisinopril, enalapril, ramipril, and captopril are used frequently in clinics since they are effective in lowering blood pressure and preserving cardiovascular health. On the global level, hypertension and cardiovascular diseases experience a steady increase, especially in the ageing population and regions with such lifestyle diseases as obesity and diabetes and therefore the use of ACE inhibitors is expected to remain high.

• They also identified that the ACE Inhibitors market is growing at a moderate pace at the worldwide level especially because of the increase in hypertension and CVD in developed and developing nations. Because of related factors such as changes in lifestyle, aging consumers, and greater incidence of obesity and diabetes hypertension has become one of the leading threats in modern-day world health issues thus consequently propelling the demand for ACE inhibitors. These medications play a vital role in the treatment of hypertension, congestive heart failure, chronic kidney diseases, and other cardiovascular diseases because this class of drugs reduces raised blood pressure and enhances the muscles of the heart. Developed countries that have integrated extensive usage of these medicines to their health systems are still using ACE inhibitors and many new developing nations are getting better access to ACE inhibitors as they upgrade the requirements of their healthcare systems and people starts toast getting better at cardiovascular pharmacology.
• Based on the market categorization, it is clear that the ACE inhibitors market consists of several opportunities and threats. The high levels of entry of generic versions especially at a time when patents of some of the most widely used ACE inhibitors are expiring has served to increase competition and therefore the cost of treatment and hence access. However, the product is facing competition from other classes of hypertensive drugs: ARBs and calcium channel blockers because a patient suffering the side effects of ACE inhibitors might switch to the competitors. Apart from factors of increase in market share and new opportunities, other factors include regulatory restraints, and positions of prices in other countries that determine the possibility of expanding the mentioned markets as well as their profitability to pharmaceutical firms. This kind of therapy is still promising; thus, companies continue to focus on the creation of new compounds the minimization of side effects, and the adoption of other complications connected with cardiovascular diseases.

Angiotensin Converting Enzymes Inhibitors Market Trend Analysis

Growing Demand for Combination Therapies in ACE Inhibitors Market

• Identified previously, there is one trend among the market dynamics that concerns the combination of ACE inhibitors with other antihypertensive agents for effective treatment. Combination drugs regimes are developing because they provide better control of blood pressure in that they influence different aspects of physiology; useful when managing complex or resistant hypertension. In these circumstances an additional antihypertensive agent is often useful, typically a calcium channel blocker or a diuretic in the company of an ACE inhibitor. This trend is fuelled by both clinical and economic benefits: The combination therapies therefore have better compliance because of fewer pills, shorter time to respond to the therapy and lastly less likelihood of other cardiovascular side effects. On the same note, for the pharmaceutical’s companies, the formulation of combination also provides them with another advantage in that such drugs are sold with a premium status and generally accorded longer patent protection than a regular ACE inhibitor.

Expanding Access to ACE Inhibitors in Emerging Markets

• The major development in the ACE inhibitors market can be e discussed in terms of a focus with the growing hypertension and cardiovascular diseases in the developing countries. Developed countries in Asia, Latin America and Africa have a Dor them increased population with hypertension and cardiovascular diseases are as a result of higher economic output, continued increase in urbanization and proved shifts in life. But in all these regions, the problem of cost still remains a primary barrier to effective medication and therefore a large gap in health needs. To reach all the above-mentioned untapped market, the efficient way is to expand the health facility network and to get governments of the world to increase their funding of public access to health care programs that these pharmaceutical makers can cover. The second and more interesting prospect for generic ACE inhibitors especially is longer and broader because they cannot but be cheaper than the actual branded ACE inhibitors. Furthermore, the advances made in campaigning for health literate environments and cardiovascular diseases will be beneficial to the growth needed as patient and healthcare consumers relay on expeditious solutions on management of high blood pressure.

Angiotensin Converting Enzymes Inhibitors Market Segment Analysis:

Angiotensin Converting Enzymes Inhibitors Market is Segmented on the basis of Drug, Indication and Distribution channel.

By drug, Benazepril, and Perindopril, segment is expected to dominate the market during the forecast period

• Some of them are in high ranking in terms of market control due to firm establishment, efficiency including script prescription ratio such as Enalapril and Lisinopril. Lisinopril and enalapril are specifically popular because of good side effect profile and documented therapeutic effect in various forms of cardiovascular disorder including hypertension, chronic heart failure, and renal disease. As the awareness of hypertension and cardiovascular diseases especially in new markets grow these drugs should continue to enjoy even more demand. The idea that this segment will remain ahead of the rest in the given time line is also backed by on-going research in a bid to discover improved formulations, better tolerability and more therapeutic application. Also, if certain types of ACE inhibitors are patented, there are expected to allow affordable generic copies tighten access in less-generous markets in the future.

By Indication, the Hypertension segment expected to held the largest share

• Impliedly, therefore, the Hypertension segment seems well poised to corner the largest market share for ACE inhibitors. The fact that hypertension is one of the diseases experienced by millions of people all over the world and within all ages is worrying. This factor has remained due to the rising risk factors such as obesity, decreased physical activity, wrong diet choices, and high stress levels among others, that continue to fuel hypertension at a global level. ACE inhibitors are possibly the most frequently used medication for hypertension, primarily because the result is a lowering of blood pressure and a mechanism of action regarding the inhibition of enzymes that cause vasoconstriction. A steady growth dynamic of the hypertension segment can be attributed to growth in health consciousness among the public and better access to tests that help identify early signs of hypertension. Some opportunities are as follows: Another interesting application is the gateway markets where essential hypertension often remains undiagnosed and undertreated, yet the market expands as soon as the healthcare needs are met.

Angiotensin Converting Enzymes Inhibitors Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• It was predicted that North America will hold the largest market share in the global ACE inhibitors market within the course of the forecast period due to the high prevalence of hypertension, cardiovascular diseases, etc. As presented in the marketable the United States dominates some of the factors such as the growing aging population, prevalence of; lifestyle diseases among the populace, and; the readily available market for quality consumer health care services to which ensure the steady market for ACE inhibitors. Cardiovascular diseases are some of the leading causes of mortality in North America and the governments and other stakeholders in the risk environment are investing a lot of money into cardiovascular diseases and preventive measures.
• The supremacy of the region is also explained by the goal-oriented perception of cardiovascular threats and protective actions, as well as the energetic approach to such fundamental testing and hypertension’s early detection. Given culture so many unhealthy lifestyles in America that cause overweighing and diabetes or hypertension, the use of antihypertensives such as ACE inhibitors may experience higher demand. Also, North America continues to observe a high growth in clinically related research activities and new drug trials that will facilitate the introduction into the market of improved formulations and combination therapies.

Active Key Players in the Angiotensin Converting Enzymes Inhibitors Market

• AbbVie Inc. (United States)
• AstraZeneca plc (United Kingdom)
• Boehringer Ingelheim GmbH (Germany)
• Bristol-Myers Squibb Company (United States)
• Cipla Limited (India)
• Daiichi Sankyo Company, Limited (Japan)
• Eli Lilly and Company (United States)
• Johnson & Johnson (United States)
• Lupin Limited (India)
• Merck & Co., Inc. (United States)
• Mylan N.V. (United States)
• Novartis International AG (Switzerland)
• Pfizer Inc. (United States)
• Sanofi S.A. (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Other Key Players

Key Industry Developments in the Angiotensin Converting Enzymes Inhibitors Market:

• In September 2023, PMS-PERINDOPRIL-INDAPAMIDE (perindopril erbumine or indapamide), a generic medication for adults, was introduced by Pharma Science Canada, a pharmaceutical firm based in Quebec, as the first line of treatment for mild to moderate essential hypertension (high blood pressure).

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Angiotensin Converting Enzymes Inhibitors Market by Drugs
 4.1 Angiotensin Converting Enzymes Inhibitors Market Snapshot and Growth Engine
 4.2 Angiotensin Converting Enzymes Inhibitors Market Overview
 4.3 Benazepril
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Benazepril: Geographic Segmentation Analysis
 4.4 Perindopril
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Perindopril: Geographic Segmentation Analysis
 4.5 Trandolapril
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Trandolapril: Geographic Segmentation Analysis
 4.6 Captopril
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Captopril: Geographic Segmentation Analysis
 4.7 Enalapril
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Enalapril: Geographic Segmentation Analysis
 4.8 Lisinopril
  4.8.1 Introduction and Market Overview
  4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.8.3 Key Market Trends, Growth Factors and Opportunities
  4.8.4 Lisinopril: Geographic Segmentation Analysis
 4.9 Others
  4.9.1 Introduction and Market Overview
  4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.9.3 Key Market Trends, Growth Factors and Opportunities
  4.9.4 Others: Geographic Segmentation Analysis

Chapter 5: Angiotensin Converting Enzymes Inhibitors Market by Indication
 5.1 Angiotensin Converting Enzymes Inhibitors Market Snapshot and Growth Engine
 5.2 Angiotensin Converting Enzymes Inhibitors Market Overview
 5.3 Hypertension
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Hypertension: Geographic Segmentation Analysis
 5.4 Coronary Artery Disease
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Coronary Artery Disease: Geographic Segmentation Analysis
 5.5 Heart Failure
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Heart Failure: Geographic Segmentation Analysis
 5.6 Chronic Kidney Disease
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Chronic Kidney Disease: Geographic Segmentation Analysis
 5.7 Scleroderma
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Scleroderma: Geographic Segmentation Analysis
 5.8 Others
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Others: Geographic Segmentation Analysis

Chapter 6: Angiotensin Converting Enzymes Inhibitors Market by Distribution Channel
 6.1 Angiotensin Converting Enzymes Inhibitors Market Snapshot and Growth Engine
 6.2 Angiotensin Converting Enzymes Inhibitors Market Overview
 6.3 Hospital Pharmacies
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
 6.4 Retail Pharmacies
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Retail Pharmacies: Geographic Segmentation Analysis
 6.5 Online Pharmacies
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Online Pharmacies: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Angiotensin Converting Enzymes Inhibitors Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ABBVIE INC (UNITED STATES)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 ASTRAZENECA PLC (UNITED KINGDOM)
 7.4 BOEHRINGER INGELHEIM GMBH (GERMANY)
 7.5 BRISTOL-MYERS SQUIBB COMPANY (UNITED STATES)
 7.6 CIPLA LIMITED (INDIA)
 7.7 DAIICHI SANKYO COMPANY
 7.8 LIMITED (JAPAN)
 7.9 ELI LILLY AND COMPANY (UNITED STATES)
 7.10 JOHNSON & JOHNSON (UNITED STATES)
 7.11 LUPIN LIMITED (INDIA)
 7.12 MERCK & CO INC (UNITED STATES)
 7.13 MYLAN N V (UNITED STATES)
 7.14 NOVARTIS INTERNATIONAL AG (SWITZERLAND)
 7.15 PFIZER INC (UNITED STATES)
 7.16 SANOFI S A (FRANCE)
 7.17 TEVA PHARMACEUTICAL INDUSTRIES LTD (ISRAEL)
 7.18 OTHER ACTIVE PLAYERS

Chapter 8: Global Angiotensin Converting Enzymes Inhibitors Market By Region
 8.1 Overview
 8.2. North America Angiotensin Converting Enzymes Inhibitors Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Drugs
  8.2.4.1 Benazepril
  8.2.4.2 Perindopril
  8.2.4.3 Trandolapril
  8.2.4.4 Captopril
  8.2.4.5 Enalapril
  8.2.4.6 Lisinopril
  8.2.4.7 Others
  8.2.5 Historic and Forecasted Market Size By Indication
  8.2.5.1 Hypertension
  8.2.5.2 Coronary Artery Disease
  8.2.5.3 Heart Failure
  8.2.5.4 Chronic Kidney Disease
  8.2.5.5 Scleroderma
  8.2.5.6 Others
  8.2.6 Historic and Forecasted Market Size By Distribution Channel
  8.2.6.1 Hospital Pharmacies
  8.2.6.2 Retail Pharmacies
  8.2.6.3 Online Pharmacies
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Angiotensin Converting Enzymes Inhibitors Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Drugs
  8.3.4.1 Benazepril
  8.3.4.2 Perindopril
  8.3.4.3 Trandolapril
  8.3.4.4 Captopril
  8.3.4.5 Enalapril
  8.3.4.6 Lisinopril
  8.3.4.7 Others
  8.3.5 Historic and Forecasted Market Size By Indication
  8.3.5.1 Hypertension
  8.3.5.2 Coronary Artery Disease
  8.3.5.3 Heart Failure
  8.3.5.4 Chronic Kidney Disease
  8.3.5.5 Scleroderma
  8.3.5.6 Others
  8.3.6 Historic and Forecasted Market Size By Distribution Channel
  8.3.6.1 Hospital Pharmacies
  8.3.6.2 Retail Pharmacies
  8.3.6.3 Online Pharmacies
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Angiotensin Converting Enzymes Inhibitors Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Drugs
  8.4.4.1 Benazepril
  8.4.4.2 Perindopril
  8.4.4.3 Trandolapril
  8.4.4.4 Captopril
  8.4.4.5 Enalapril
  8.4.4.6 Lisinopril
  8.4.4.7 Others
  8.4.5 Historic and Forecasted Market Size By Indication
  8.4.5.1 Hypertension
  8.4.5.2 Coronary Artery Disease
  8.4.5.3 Heart Failure
  8.4.5.4 Chronic Kidney Disease
  8.4.5.5 Scleroderma
  8.4.5.6 Others
  8.4.6 Historic and Forecasted Market Size By Distribution Channel
  8.4.6.1 Hospital Pharmacies
  8.4.6.2 Retail Pharmacies
  8.4.6.3 Online Pharmacies
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Angiotensin Converting Enzymes Inhibitors Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Drugs
  8.5.4.1 Benazepril
  8.5.4.2 Perindopril
  8.5.4.3 Trandolapril
  8.5.4.4 Captopril
  8.5.4.5 Enalapril
  8.5.4.6 Lisinopril
  8.5.4.7 Others
  8.5.5 Historic and Forecasted Market Size By Indication
  8.5.5.1 Hypertension
  8.5.5.2 Coronary Artery Disease
  8.5.5.3 Heart Failure
  8.5.5.4 Chronic Kidney Disease
  8.5.5.5 Scleroderma
  8.5.5.6 Others
  8.5.6 Historic and Forecasted Market Size By Distribution Channel
  8.5.6.1 Hospital Pharmacies
  8.5.6.2 Retail Pharmacies
  8.5.6.3 Online Pharmacies
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Angiotensin Converting Enzymes Inhibitors Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Drugs
  8.6.4.1 Benazepril
  8.6.4.2 Perindopril
  8.6.4.3 Trandolapril
  8.6.4.4 Captopril
  8.6.4.5 Enalapril
  8.6.4.6 Lisinopril
  8.6.4.7 Others
  8.6.5 Historic and Forecasted Market Size By Indication
  8.6.5.1 Hypertension
  8.6.5.2 Coronary Artery Disease
  8.6.5.3 Heart Failure
  8.6.5.4 Chronic Kidney Disease
  8.6.5.5 Scleroderma
  8.6.5.6 Others
  8.6.6 Historic and Forecasted Market Size By Distribution Channel
  8.6.6.1 Hospital Pharmacies
  8.6.6.2 Retail Pharmacies
  8.6.6.3 Online Pharmacies
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Angiotensin Converting Enzymes Inhibitors Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Drugs
  8.7.4.1 Benazepril
  8.7.4.2 Perindopril
  8.7.4.3 Trandolapril
  8.7.4.4 Captopril
  8.7.4.5 Enalapril
  8.7.4.6 Lisinopril
  8.7.4.7 Others
  8.7.5 Historic and Forecasted Market Size By Indication
  8.7.5.1 Hypertension
  8.7.5.2 Coronary Artery Disease
  8.7.5.3 Heart Failure
  8.7.5.4 Chronic Kidney Disease
  8.7.5.5 Scleroderma
  8.7.5.6 Others
  8.7.6 Historic and Forecasted Market Size By Distribution Channel
  8.7.6.1 Hospital Pharmacies
  8.7.6.2 Retail Pharmacies
  8.7.6.3 Online Pharmacies
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research